Role of interleukin-1/interleukin-1 receptor antagonist family of cytokines in long-term continuous glucose monitoring in vivo

Journal of Diabetes Science and Technology

Volumn 7, Issue 6, 2013, Pages 1538-1546

  Klueh, Ulrike ^a   Antar, Omar ^a   Qiao, Yi ^a   Kreutzer, Donald L ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Biosensor; Continuous glucose monitoring; Diabetes; Fibrosis; Inflammation

Indexed keywords

GLUCOSE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; CONTINUOUS GLUCOSE MONITORING; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TISSUE REACTION;

ANIMALS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CYTOKINES; FEMALE; FIBROSIS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; PROSTHESES AND IMPLANTS; REPRODUCIBILITY OF RESULTS; WOUND HEALING;

EID: 84893662135     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700614     Document Type: Article

References (31)

1. Li J, Chen J, Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol. 2007;25(1):9-18.
2. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585-601.
3. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression. Cancer Res. 2007;67(20):10019-26.
4. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-52.
5. Arend WP, Gabay C. Physiologic role of interleukin-1 receptor antagonist. Arthritis Res. 2000;2(4):245-8.
6. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis. 2000;59 Suppl 1:i60-4.
7. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem. 1995;270(23):13757-65.
8. Martin MU, Falk W. The interleukin-1 receptor complex and interleukin-1 signal transduction. Eur Cytokine Netw. 1997;8(1):5-17.
9. Muzio M, Polentarutti N, Facchetti F, Peri G, Doni A, Sironi M, Transidico P, Salmona M, Introna M, Mantovani A. Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. Eur J Immunol. 1999;29(3):781-8.
10. Muzio M, Polentarutti N, Sironi M, Poli G, De Gioia L, Introna M, Mantovani A, Colotta F. Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J Exp Med. 1995;182(2):623-8.
11. Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem. 1997;272(12):7727-31.
12. Klueh U, Liu Z, Feldman B, Kreutzer D. Importance of interleukin-1 and interleukin-1 receptor antagonist in short-term glucose sensor function in vivo. J Diabetes Sci Technol. 2010;4(5):1073-86.
13. Klueh U, Kaur M, Qiao Y, Kreutzer DL. Critical role of tissue mast cells in controlling long-term glucose sensor function in vivo. Biomaterials. 2010;31(16):4540-51.
14. Klueh U, Liu Z, Cho B, Ouyang T, Feldman B, Henning TP, Kaur M, Kreutzer D. Continuous glucose monitoring in normal mice and mice with prediabetes and diabetes. Diabetes Technol Ther. 2006;8(3):402-12.
15. Cunningham DD, Stenken JA. In vivo glucose sensing. In: Winefordner JD, ed. Chemical analysis: a series of monographs on analytical chemistry and its applications. Hoboken: John Wiley and Sons; 2009, 454.
16. Klueh U, Liu Z, Ouyang T, Cho B, Feldman B, Henning TP, Kreutzer D. Blood-induced interference of glucose sensor function in vitro: implications for in vivo sensor function. J Diabetes Sci Technol. 2007;1(6):842-9.
17. Klueh U, Kaur M, Montrose DC, Kreutzer DL. Inflammation and glucose sensors: use of dexamethasone to extend glucose sensor function and life span in vivo. J Diabetes Sci Technol. 2007;1(4):496-504.
18. Friedl KE. Corticosteroid modulation of tissue responses to implanted sensors. Diabetes Technol Ther. 2004;6(6):898-901.
19. McGregor VP, Banarer S, Cryer PE. Elevated endogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia. Am J Physiol Endocrinol Metab. 2002;282(4):E770-7.
20. Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Foster PS, Kumar RK. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma. Clin Exp Allergy. 2008;38(5):847-56.
21. Smith SJ, Piliponsky AM, Rosenhead F, Elchalal U, Nagler A, Levi-Schafer F. Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin Exp Allergy. 2002;32(6):906-13.
22. Yi ES, Remick DG, Lim Y, Tang W, Nadzienko CE, Bedoya A, Yin S, Ulich TR. The intratracheal administration of endotoxin: X. Dexamethasone downregulates neutrophil emigration and cytokine expression in vivo. Inflammation. 1996;20(2):165-75.
23. Langereis JD, Oudijk EJ, Schweizer RC, Lammers JW, Koenderman L, Ulfman LH. Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1β synthesis by human neutrophils. Eur Respir J. 2011;37(2):406-15.
24. Newman SP, Flower RJ, Croxtall JD. Dexamethasone suppression of IL-1β-induced cyclooxygenase 2 expression is not mediated by lipocortin-1 in A549 Cells. Biochem Biophys Res Commun. 1994;202(2):931-9.
25. Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003;124(4):1526-32.
26. O'Neill LA. Molecular mechanisms underlying the actions of the pro-inflammatory cytokine interleukin 1. Royal Irish Academy Medal Lecture. Biochem Soc Trans. 1997;25(1):295-302.
27. Rutter JL, Benbow U, Coon CI, Brinckerhof CE. Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells. J Cell Biochem. 1997;66(3):322-36.
28. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, Blasi F. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J. 1992;11(1):205-13.
29. Nguyen M, Corless CL, Kräling BM, Tran C, Atha T, Bischof J, Barsky SH. Vascular expression of E-selectin is increased in estrogen-receptor-negative breast cancer: a role for tumor-cell-secreted interleukin-1 alpha. Am J Pathol. 1997;150(4):1307-14.
30. Rangnekar VV, Waheed S, Davies TJ, Toback FG, Rangnekar VM. Antimitogenic and mitogenic actions of interleukin-1 in diverse cell types are associated with induction of gro gene expression. J Biol Chem. 1991;266(4):2415-22.
31. Sica A, Matsushima K, Van Damme J, Wang JM, Polentarutti N, Dejana E, Colotta F, Mantovani A. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology. 1990;69(4):548-53.